Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
Frasci G, Comella P, D'Aiuto G, Thomas R, Capasso I, Elmo M, Botti G, Cortino GR, Lapenta L, De Rosa V, Vallone P, Petrillo A, Comella G. Frasci G, et al. Among authors: thomas r. Ann Oncol. 2000 Mar;11(3):367-71. doi: 10.1023/a:1008346708604. Ann Oncol. 2000. PMID: 10811508 Free article. Clinical Trial.
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G, Comella P, Thomas R, Di Bonito M, Lapenta L, Capasso I, Botti G, Vallone P, De Rosa V, D'Aiuto G, Comella G. Frasci G, et al. Among authors: thomas r. Cancer Chemother Pharmacol. 2004 Jan;53(1):25-32. doi: 10.1007/s00280-003-0669-x. Epub 2003 Sep 26. Cancer Chemother Pharmacol. 2004. PMID: 14513281 Clinical Trial.
Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study.
Frasci G, D'Aiuto G, Comella P, Thomas R, Capasso I, Botti G, Cortino GR, De Rosa V, Comella G; Southern Italy Cooperative Oncology Group; National Tumor Institute of Naples. Frasci G, et al. Among authors: thomas r. Semin Oncol. 2001 Jun;28(3 Suppl 10):50-6. doi: 10.1053/sonc.2001.22533. Semin Oncol. 2001. PMID: 11510034 Clinical Trial.
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
Nuzzo F, Morabito A, De Maio E, Di Rella F, Gravina A, Labonia V, Landi G, Pacilio C, Piccirillo MC, Rossi E, D'Aiuto G, Thomas R, Gori S, Colozza M, De Placido S, Lauria R, Signoriello G, Gallo C, Perrone F, de Matteis A. Nuzzo F, et al. Among authors: thomas r. Crit Rev Oncol Hematol. 2008 May;66(2):171-80. doi: 10.1016/j.critrevonc.2007.10.006. Epub 2007 Dec 21. Crit Rev Oncol Hematol. 2008. PMID: 18160303 Clinical Trial.
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Nuzzo F, Morabito A, Gravina A, Di Rella F, Landi G, Pacilio C, Labonia V, Rossi E, De Maio E, Piccirillo MC, D'Aiuto G, Thomas R, Rinaldo M, Botti G, Di Bonito M, Di Maio M, Gallo C, Perrone F, de Matteis A. Nuzzo F, et al. Among authors: thomas r. BMC Cancer. 2011 Feb 16;11:75. doi: 10.1186/1471-2407-11-75. BMC Cancer. 2011. PMID: 21324184 Free PMC article. Clinical Trial.
8,228 results